Riverpoint deal and AI orders accelerate the Novanta thesis
- Novanta is a picks-and-parts supplier for medical device makers and advanced industrial OEMs.
- The Riverpoint Medical acquisition expands medical exposure to 60% and doubles recurring consumables revenue to $300 million.
- GenAI infrastructure now makes up 17% of total sales and is growing 25% year over year.
- The company received its first major servo drive orders for training humanoid robots.
- Management expects price surcharges to drive gross margins back to 48% in the second half of 2026.
A stronger portfolio with higher medical exposure
The investment picture for Novanta continues to improve. The company delivered 9% organic growth in the second quarter of 2026. Closing the transformative Riverpoint Medical acquisition fundamentally shifted the portfolio, pushing total medical exposure to 60%.
The automation side of the business is also gaining momentum. GenAI infrastructure applications now make up about 17% of total sales and are growing 25% year over year. Novanta also logged its first significant servo drive orders for training humanoid robots, validating its role in the physical AI build-out.
The bear case focuses on margin pressure and pricing power. The company faces a negative price and cost gap due to volatile freight and tariff environments. Management expects price surcharges to push gross margins back to 48% in the second half of 2026, but investors need to see those charges successfully pass to OEM customers.
Precision parts for long OEM programs
Novanta makes critical components and subsystems that other companies build into their own machines. Its customers are mainly OEMs, meaning original equipment manufacturers. These buyers care about precision, safety, reliability, and long product lives.
The model works best when Novanta wins a spot inside a customer platform that ships for years. A medical device or factory tool can take a long time to design and approve. Once Novanta is built in, switching suppliers can be costly and risky for the customer.
That strength can also become a weakness. If a customer delays a machine launch, cuts orders, or pushes back on price surcharges, Novanta feels it. The company relies heavily on the industrial automation, semiconductor tool, and AI infrastructure markets.
What Novanta sells
Laser and photonics components
These include laser beam delivery parts and related optical systems. They are used in precision industrial and medical applications where accuracy matters.
Encoders, motors, and servo drives
These products help machines know where they are and move with high precision. The segment recently saw significant new orders for training humanoid robots.
Air bearing spindles and semiconductor parts
These are used in manufacturing tasks such as GPU drilling, probe card production, and lithography. This ties Novanta to the secular growth of GenAI hardware.
Insufflators, pumps, and surgical systems
These medical products support minimally invasive surgery. Next-generation insufflators remain a core driver inside Medical Solutions.
Medical consumables and implantables
The Riverpoint acquisition added innovative fiber-based sutures and implantables for sports medicine, cardiovascular, and orthopedic uses. This doubles recurring consumables revenue to approximately $300 million.
Medical growth takes the lead
The segment shares reflect the expected run rate following the July 2026 close of the Riverpoint Medical acquisition, which expands medical end market exposure to roughly 60% of total revenue.
What could break the thesis
Surcharges fail to catch costs
High impact · Medium oddsGross margin has been hurt by freight, tariffs, and material costs. Management expects price surcharges to drive a recovery to 48% margins in the second half of 2026. If OEM customers resist those charges, the margin recovery could miss.
AI infrastructure orders cool down
High impact · Medium oddsGenAI infrastructure is now 17% of sales and growing 25% year over year. That is helpful, but it could reflect urgent early build-outs rather than a long cycle. If prototype work does not become production volume, the automation bull case weakens.
Riverpoint integration delays
Medium impact · Medium oddsNovanta just closed the transformative Riverpoint Medical acquisition to double its recurring consumables revenue. Large deals bring execution risk. Any delay in realizing synergies or margin accretion could pressure the stock.
Supply chain and energy shocks
Medium impact · Medium oddsThe company previously warned about geopolitical conflicts raising global energy prices and freight costs. Novanta does not have material Middle East operations, but wider conflicts could hit supply lines before pricing resets.
In one breath
What does Novanta actually do?
Novanta makes precision components and subsystems for medical and advanced industrial OEMs. Its products help machines see, move, measure, cut, drill, pump, and control with high accuracy.
How is Novanta connected to AI?
GenAI infrastructure is roughly 17% of total sales and growing 25% year over year. The exposure includes semiconductor manufacturing tools, GPU-related drilling, and servo drives for training humanoid robots.
Why did the Novanta thesis improve in Q2 2026?
The company delivered 9% organic growth and closed the Riverpoint Medical acquisition. That deal doubles recurring medical consumables to $300 million and pushes overall medical exposure to 60%.
What is the biggest thing to watch next?
Watch whether gross margin reaches the 48% target in the second half of 2026. The company needs price surcharges and facility closures to offset tariffs, freight, and material cost pressure.
